The initiation of coverage by a reputable analyst firm like HC Wainwright & Co. with a Buy rating and a significant price target suggests a positive outlook for Sagimet Biosciences. This endorsement is likely to generate investor interest and could lead to a short-term increase in the stock price, reflecting the analyst's bullish stance.